Purpose: The pharmacology, pharmacokinetics, efficacy and tolerability, safety, drug interactions, dosage and administration, cost, and place in therapy of insulin detemir are reviewed.

Semglee's latest approval follows the publication of FDA guidance that spelled out what would be required for an abbreviated review for a fully interchangeable insulin product. The agency has also ...

Trials including commercially available formulations of insulin detemir or insulin glargine were compared with NPH. Pertinent English-language clinical trials published between 2000 and 2006 were ...

Such forward looking statements may include statements about the approval for the first interchangeable biosimilar Semglee (insulin glargine-yfgn injection) for the treatment of diabetes ...

Use of the long-acting insulin analogs glargine and detemir does not reduce the risk of diabetic ketoacidosis in children and adolescents with type 1 diabetes mellitus (T1DM), compared with the ...